Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial

Eugenia Bruzzese, Valeria Raia, Eliana Ruberto, Riccardo Scotto, Antonietta Giannattasio, Dario Bruzzese, Maria Cristina Cavicchi, Michela Francalanci, Carla Colombo, Nadia Faelli, Valeria Dacco`, Giuseppe Magazzu`, Stefano Costa, Vincenzina Lucidi, Fabio Majo, Alfredo Guarino

Research output: Contribution to journalArticle

Abstract

Background: Intestinal dysbiosis has been described in Cystic Fibrosis (CF) and probiotics have been proposed to restore microbial composition. Aim of the study was to investigate the effects of Lactobacillus rhamnosus GG (LGG) on clinical outcomes in children with cystic fibrosis (CF). Methods: A multicentre, randomised double-blind, clinical trial was conducted in children with CF. After 6months of baseline assessment, enrolled children (2 to 16years of age) received Lactobacillus GG (6×109 CFU/day) or placebo for 12months. Primary outcomes were proportion of subjects with at least one pulmonary exacerbation and hospitalisation over 12months. Secondary endpoints were total number of exacerbations and hospitalisations, pulmonary function, and nutritional status. Results: Ninety-five patients were enrolled (51/95 female; median age of 103. ±. 50. months). In a multivariate GEE logistic analysis, the odds of experiencing at least one exacerbation was not significantly different between the two groups, also after adjusting for the presence of different microbial organisms and for the number of pulmonary exacerbations within 6. months before randomisation (OR 0.83; 95% CI 0.38 to 1.82, p = 0.643). Similarly, LGG supplementation did not significantly affect the odds of hospitalisations (OR 1.67; 95% CI 0.75 to 3.72, p = 0.211). No significant difference was found for body mass index and FEV1. Conclusions: LGG supplementation had no effect on respiratory and nutritional outcomes in this large study population of children with CF under stringent randomised clinical trial conditions. Whether earlier interventions, larger doses, or different strains of probiotics may be effective is unknown.

Original languageEnglish
Pages (from-to)375-382
JournalJournal of Cystic Fibrosis
Volume17
Issue number3
DOIs
Publication statusPublished - 2018

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Bruzzese, E., Raia, V., Ruberto, E., Scotto, R., Giannattasio, A., Bruzzese, D., Cavicchi, M. C., Francalanci, M., Colombo, C., Faelli, N., Dacco`, V., Magazzu`, G., Costa, S., Lucidi, V., Majo, F., & Guarino, A. (2018). Lack of efficacy of Lactobacillus GG in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial. Journal of Cystic Fibrosis, 17(3), 375-382. https://doi.org/10.1016/j.jcf.2017.10.014